The effect of pharmacological treatment in the compensation of vertigo 

Pons Rocher F.

Servicio de O.R.L. 
Hospital Dr. Peset-S.V.S. Valencia.
An Otorrinolaringol Ibero Am 1999;26(3):271-91

Abstract

From the age of sixty, vertigo is mainly due to vertebro-basilar insufficiency.  It has been described that the association of Dihydroergocristine-Piracetam (D-P) is a useful treatment for vertebro-basilar insufficiency. That is why we have designed a comparative study between D-P an a Placebo, so that to prove if this association can be useful in the treatment of vertigo occasioned by cerebrovascular insufficiency. Fifty patients complaining of vertigo were included in the study after an untreated term. 19 received a daily capsule of Placebo, and the other 31, treated with D-P, were divided in two groups: 16 patients received a dose of 3 mg Dihydroergocristine + 1.6 g piracetam every 12 hours per os; and 15 other were treated with 1.5 mg Dihydroergocristine + 0.8 g piracetam every 8 hours during 90 days. The patients were evaluated at the beginning of the study and 90 days later, with anamnesis and vestibular tests.  In the last consultation the patients autoevaluated themselves the effect and the tolerance to the drugs received.  In the Placebo group it was observed an improvement or disappearance of vertiginous symptoms in the 68.5% of the cases, while with D-P was 93.7% at the dose of 3 mg Dihydroergocristine + 1.6 g piracetam each 12 hours and 100% with the dose 1.5 mg Dihydroergocristine + 0.8 g piracetam each 8 hours.  None of the treated patients with D-P worsened their symptoms. We observe a considerable decrease in the number of patients with vegetative symptoms in the group treated with D-P related to the Placebo group, though the symptoms persisted more time in the group treated with D-P that in the Placebo group. The group treated with D-P get a higher percentage of improvements and disappearance of auditive and cervical symptoms that the groups treated with Placebo.  In the vestibulo-spinal and cerebellous tests it was observed a better improvement with D-P at the dose of 1.5 mg of Dihydroergocristine + 0.8 g piracetam each hours compared with the other two groups.  It can be concluded that the association D-P is an effective treatment for vertigo, getting also a higher normalization of the vestibular tests than Placebo.

Galantamine | Vinpocetine | Picamilon | Idebenone | Pyritinol | Modafinil | Deprenyl  
Home |
Order
 

Alzheimer's disease
piracetam  and Alzheimer's 
piracetam  therapy in Alzheimer's
piracetam  use in Alzheimer's
piracetam  induced changes in Alzheimer's
piracetam  effect on Alzheimer's
piracetam  reverses hippocampal changes in Alzheimer's
piracetam  and Alzheimer's disease
piracetam  controlled study on dementia
piracetam  effect on senile dementia memory
Alcoholism
piracetam  in acute alcohol withdrawal
piracetam  alcoholic treatment
piracetam  efficacy in chronic alcoholics
piracetam  effect on alcoholics
Child birth
piracetam  in parturients and newborn infants
piracetam  reduced duration of labor
piracetam  protective effect during delivery
piracetam  concentrations during delivery
Circulatory Disorders
piracetam  effectiveness in cerebral arteriosclerosis
piracetam  and chronic cerebrovascular disorders
piracetam  effect on brain circulation failure
Dyslexia
piracetam  learning aid in dyslexia
piracetam  in children with dyslexia
piracetam  in students with dyslexia
piracetam  efficacy in dyslexic reading and writing disorders
piracetam  verbal effect in dyslexic boys
piracetam  improves reading in dyslexia
Head injury
piracetam  and concussion
piracetam  effect on consciousness due to head injury
piracetam  protection in brain injury
piracetam  use in severe brain injury
Hearing loss
piracetam  use in sudden deafness
piracetam  sudden hearing loss treatment
piracetam  in tinnitus and sudden deafness
piracetam  treatment of sudden deafness
Heart Disease
piracetam  effects on arterial hypertension
piracetam  effect on elderly coronary heart disease
piracetam  in chronic ischemic heart disease
piracetam  in ischemic heart disease
piracetam  in myocardial infarct patients
Mental Performance
piracetam  improved mental performance
piracetam  and nootropics
piracetam  in patients with mental decline 
piracetam  effects on cognitive functions
piracetam  improves memory
piracetam  efficacy in cognitive impairment
piracetam  memory impairment trial
piracetam  and EEG of boys with learning disorders
piracetam  effect on adolescent brain function
piracetam  effects on human EEG
piracetam  on change in brain functional state
piracetam  effects on brain functions
piracetam  in elderly cerebral impairment
piracetam  in cerebral impairment
Stroke
piracetam  in secondary stroke prophylaxis
piracetam  improves blood flow of post-stroke patients
piracetam  improves aphasia in acute stroke
piracetam  in the treatment of acute stroke
piracetam  evaluation in acute stroke
piracetam  in stroke-unduced Aphasia
piracetam  treatment in ischemic stroke
piracetam  treatment of patients with an ischemic stroke
piracetam  acute stroke study
piracetam  effect on post-stroke recovery
piracetam  improvement in Stroke
piracetam  adjuvant to language therapy for aphasia
Vertigo
piracetam  treatment for vertigo
piracetam  is effective in vertigo
piracetam  effect in 55 vertigo patients
piracetam  subjective improvement in vertigo
piracetam  significantly reduced vertigo symptoms
Myoclonus
piracetam  and reduction of myoclonus
piracetam  relieves symptoms in myoclonus epilepsy
piracetam  in cortical myoclonus
piracetam  and progressive myoclonus epilepsy
piracetam  in patients with myoclonus
piracetam  in progressive myoclonus epilepsy
piracetam  promising results in myoclonus epilepsy
piracetam  long-term efficacy in myoclonus epilepsy
piracetam  beneficial use for severe myoclonus epilepsy
piracetam  beneficial effect on post-ischaemic myoclonus
Raynaud's
piracetam  treatment of Raynaud's
piracetam  evidence for its anti-platelet effect in Raynaud's
piracetam  platelet anti-aggregant properties
Sickle Cell disease
piracetam  treatment of children with sickle cell disease
piracetam  improves sickle cell deformability
piracetam  crises management of sickle cell disease
Misc.
piracetam  mechanism of action
piracetam  elevates cholinergic receptor density
piracetam  cholinergic receptor function in mice
piracetam  effects on schizophrenia
piracetam  effect on cerebral glucose utilization
piracetam  improved driving in elderly motorists
piracetam  unique mode of action
piracetam  study age-related memory disorders
piracetam  psychological treatment
piracetam  and aging
piracetam  and vigilance
piracetam  versus acetylcholinesterase inhibitors
piracetam  effects on arterial hypertension
piracetam  in cerebral palsy
piracetam  auxiliary treatment of cerebral palsy
piracetam  interaction in the motor cortex
piracetam  effect on consciousness after neurosurgery
piracetam  effect on cerebral infarction
piracetam  improves cognitive deficits in early Parkinsonism
piracetam  therapy in recurrent duodenal ulcer
piracetam  efficacy in recurrence of duodenal ulcer
piracetam  efficacy in breath-holding spells
piracetam  treatment of migraine
piracetam  treatment of soft tissue rheumatism 
piracetam  effect on intellectually deficient children
piracetam  effect on neuroleptic-induced side effects
piracetam  improved school-performance in legasthenia

Galantamine | Vinpocetine | Picamilon | Idebenone | Pyritinol | Modafinil | Deprenyl
Home |
Order

 

 

 

Hit Counter